Home›Legal›Tirzepatide in New York
Tirzepatide in New York: Legal Status & Provider Guide (2026)
Quick Answer
Tirzepatide is a prescription substance in the United States. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. The compounding shortage exemption expired in early 2025. Current federal law generally prohibits compounded tirzepatide outside of narrow exceptions. Providers offering compounded tirzepatide should have clear documentation of their legal basis. In New York, compounding is governed by the New York State Board of Pharmacy (NYSBP). New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.
Federal Legal Status
FDA Approval Status
FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). FDA declared the tirzepatide shortage resolved in December 2024.
Compounding Pharmacy Rules (Federal)
Compounded tirzepatide was broadly permitted during the shortage period. Following FDA's shortage resolution in December 2024, 503B outsourcing facilities had until February 18, 2025, and 503A pharmacies until March 19, 2025, to wind down compounding. As of mid-2025, compounded tirzepatide is generally prohibited except for narrow clinical exceptions under a valid prescription.
Also Known As
Mounjaro · Zepbound
Primary Research Areas
- Weight management
- Type 2 diabetes
- Metabolic health
- Insulin resistance
New York Pharmacy Board & Compounding Rules
Compounding Overview
New York has among the most stringent pharmacy and prescribing regulations in the country. The New York State Board of Pharmacy enforces USP 797 and 795 standards and requires all compounding pharmacies to meet detailed quality and documentation requirements. New York has been particularly active in enforcing against unapproved compounded medications. In-state telehealth peptide providers are subject to strict New York Medical Board oversight.
Notable Rules
- New York requires compounding pharmacies to register separately for sterile compounding.
- The New York Department of Health has enforcement authority over unlicensed pharmaceutical activity.
- New York has stricter-than-federal requirements for documentation of medical necessity for compounded preparations.
- Interstate prescribing into New York requires a New York state license.
- New York and Pennsylvania maintain reciprocal pharmacy licensure recognition for some categories.
Prescribing Requirements in New York
New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.
About Tirzepatide
Tirzepatide is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly. It has demonstrated significant efficacy in clinical trials for both glycemic control and weight reduction, with some studies showing superior weight loss compared to semaglutide.
For more research information, mechanism of action, and provider availability, see the Tirzepatide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded tirzepatide legal in 2026?
- FDA declared the tirzepatide shortage resolved in December 2024. Wind-down periods ended in Q1 2025. As of mid-2025, compounded tirzepatide is generally prohibited except for documented clinical exceptions. Patients should verify the legal basis with their provider.
- What is the difference between Mounjaro and Zepbound?
- Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes management; Zepbound is approved for chronic weight management in adults with obesity or overweight with a related condition. The drugs are chemically identical.
Tirzepatide Providers in New York
No providers currently listed in New York for Tirzepatide. Browse the full directory to find providers offering Tirzepatide.
Browse all Tirzepatide providers →Tirzepatide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Tirzepatide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .